Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Other Gross PP&E Adjustments (2022 - 2025)

Historic Other Gross PP&E Adjustments for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $200.0 million.

  • Indivior Pharmaceuticals' Other Gross PP&E Adjustments rose 61282.05% to $200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.0 million, marking a year-over-year increase of 61282.05%. This contributed to the annual value of $144.0 million for FY2024, which is 2100.84% up from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Other Gross PP&E Adjustments stood at $200.0 million, which was up 61282.05% from $175.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' Other Gross PP&E Adjustments' 5-year high stood at $200.0 million during Q3 2025, with a 5-year trough of -$39.0 million in Q3 2024.
  • Moreover, its 4-year median value for Other Gross PP&E Adjustments was -$31.0 million (2022), whereas its average is $54.0 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Other Gross PP&E Adjustments tumbled by 2187.5% in 2024 and then surged by 61470.59% in 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' Other Gross PP&E Adjustments (Quarter) stood at -$31.0 million in 2022, then soared by 483.87% to $119.0 million in 2023, then rose by 21.01% to $144.0 million in 2024, then surged by 38.89% to $200.0 million in 2025.
  • Its Other Gross PP&E Adjustments stands at $200.0 million for Q3 2025, versus $175.0 million for Q2 2025 and $160.0 million for Q1 2025.